All In MedTech

Device Trial Radar · NCT06216301

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingTitle says "pivotal". Randomized with 734 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

734

Planned (sponsor's estimate)

Start

Jul 31, 2024

Primary completion

Oct 2028

Study completion Oct 2028

Sponsor

Lead sponsor
NovoCure GmbHNot on our public-company list
Sponsor type
Industry
First posted
Jan 22, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advanced non-small cell lung cancer that has spread to other parts of the body. The primary goals of the study are to assess overall survival and progression-free survival. Secondary objectives include analyzing outcomes based on the specific histology (subtype) of the lung cancer.

Conditions

  • Metastatic Non-small Cell Lung Cancer

Interventions

  • NovoTTF-200TDevice

    The NovoTTF-200T is a portable, battery operated system intended for continuous home use, which delivers TTFields at a frequency of 150kHz to the subject by means of insulated transducer arrays. TTFields physically disrupt the rapid cell division exhibited by cancer cells. The physical disruption induced by TTFields can lead to to downstream immunogenic cell death.

  • PembrolizumabDrug

    Pembrolizumab is an immune checkpoint inhibitor that helps the immune system recognize and attack cancer cells.

  • Platinum based chemotherapyDrug

    Platinum-based chemotherapy is a standard chemotherapy regimen commonly used in the treatment of non-small cell lung cancer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: up to 6 years
  2. Progression Free Survival (PFS)Time frame: up to 6 years

Locations

107 sites in 17 countries. Site status is shown where the registry gives one.

  • Central Alabama Research

    Birmingham, Alabama · Terminated

  • Western Regional Medical Center, LLC

    Goodyear, Arizona · Active not recruiting

  • St. Jude Herritage Medical Group

    Fullerton, California · Recruiting

104 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.